Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Biocytogen and Sihuan partner to advance new therapeutics for weight loss
  • M&A / Deals

Biocytogen and Sihuan partner to advance new therapeutics for weight loss

Pharmaceutical Business Review

Under the agreement, Biocytogen's fully human antibody discovery platform will be combined with Sihuan Pharmaceutical's capabilities in drug development, manufacturing, and commercialisation.

M&A / DealsMetabolic & GLP-1Read full story

pharminent April 2, 2026 (Last updated: April 2, 2026)

Pharmaceutical Business Review

Under the agreement, Biocytogen’s fully human antibody discovery platform will be combined with Sihuan Pharmaceutical’s capabilities in drug development, manufacturing, and commercialisation.

M&A / DealsMetabolic & GLP-1Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Threat of Trump’s pharma tariffs looms again
Next: Merck KGaA acquires JSR chromatography business

Related Stories

  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • M&A / Deals

CordenPharma inks AmbioPharm buyout to continue peptide production expansion

pharminent June 1, 2026
  • M&A / Deals

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

pharminent June 1, 2026

You May Have Missed

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • Clinical Data

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

pharminent June 2, 2026
  • Clinical Data

ASCO26: In vivo oncology approaches continue to show promise

pharminent June 2, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.